Mariann Rutka

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center

Klaudia Farkas, Mariann Rutka, Anita Bálint et al. · Expert Opinion on Biological Therapy · 2015 · 92 citations

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

Klaudia Farkas, Mariann Rutka, Petra A. Golovics et al. · Journal of Crohn s and Colitis · 2016 · 81 citations · Full text

A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer

Anita Annaházi, Szabolcs Ábrahám, Klaudia Farkas et al. · British Journal of Cancer · 2016 · 59 citations · Full text

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

Lóránt Gönczi, K Gecse, Zsuzsanna Végh et al. · Inflammatory Bowel Diseases · 2017 · 56 citations · Full text

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Lóránt Gönczi, Zsuzsanna Végh, Petra A. Golovics et al. · Journal of Crohn s and Colitis · 2016 · 48 citations · Full text